Inogatran
Modify Date: 2024-01-11 18:28:11
Inogatran structure
|
Common Name | Inogatran | ||
|---|---|---|---|---|
| CAS Number | 155415-08-0 | Molecular Weight | 438.56400 | |
| Density | 1.36g/cm3 | Boiling Point | N/A | |
| Molecular Formula | C21H38N6O4 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of InogatranInogatran is a synthetic thrombin inhibitor, developed for the possible treatment and prophylaxis of arterial and venous thrombotic diseases. |
| Name | 2-[[(2R)-3-cyclohexyl-1-[(2S)-2-[3-(diaminomethylideneamino)propylcarbamoyl]piperidin-1-yl]-1-oxopropan-2-yl]amino]acetic acid |
|---|---|
| Synonym | More Synonyms |
| Description | Inogatran is a synthetic thrombin inhibitor, developed for the possible treatment and prophylaxis of arterial and venous thrombotic diseases. |
|---|---|
| Related Catalog | |
| In Vivo | Inogatran (0.075, 0.25, 0.75 mg/kg, i.v.) results in dose-dependent increases in activated partial thromboplastin time (aPTT), thrombin time (TT), and prothrombin time (PT) in a canine electrolytic injury model of venous thrombosis[1]. Inogatran dose-dependently inhibits thrombus formation, which is measured as an increase in time to occlusion (TTO) and a decrease in thrombus weight. Inogatran also improves vena caval blood flow and reduces the overall incidence of thrombotic occlusion in a rat model[2]. |
| References |
| Density | 1.36g/cm3 |
|---|---|
| Molecular Formula | C21H38N6O4 |
| Molecular Weight | 438.56400 |
| Exact Mass | 438.29500 |
| PSA | 164.13000 |
| LogP | 2.73010 |
| Index of Refraction | 1.632 |
| Storage condition | 2-8℃ |
| N-((1R)-2-Cyclohexyl-1-(((2S)-2-((3-guanidinopropyl)carbamoyl)piperidino)carbonyl)ethyl)glycine |
| Inogatran [INN] |
| {[(1R)-2-((2S)-2-{[(3-{[AMINO(IMINO)METHYL]AMINO}PROPYL)AMINO]CARBONYL}PIPERIDINYL)-1-(CYCLOHEXYLMETHYL)-2-OXOETHYL]AMINO}ACETIC ACID |
| IGN |
| Inogatran |